Neurocrine Biosciences (NBIX) Q1 FY26 earnings call

Neurocrine Biosciences delivered a record-setting quarter, driven by strong commercial performance of INGREZZA and CRENESITY, which exceeded $800 million in net product sales. The company is also advancing a robust pipeline with multiple new clinical programs and significant data readouts anticipated in 2027, reinforcing its strategy to diversify revenue and expand its therapeutic footprint. The pending acquisition of Soleno Therapeutics is on track to close in Q2, further strengthening the commercial portfolio.